Chemical formula: C₂₇H₃₆N₆O₃S Molecular mass: 524.678 g/mol PubChem compound: 16722836
Fedratinib is indicated for:
Population group: only adults (18 years old or older)
Fedratinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Fedratinib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
